aggressive NK-cell leukemia
diseaseOn this page
Also known as aggressive natural killer cell leukaemiaaggressive natural killer cell leukemiaaggressive NK cell leukaemiaaggressive NK cell leukemiaaggressive NK-cell leukaemia (morphologic abnormality)aggressive NK-cell leukemia (morphologic abnormality)aggressive NK-cell leukemia/lymphomaaggressive NK-cell lymphomaANKCLANKLleukaemia (disease) of natural killer cellleukemia (disease) of natural killer cellnatural killer cell leukaemia (disease)natural Killer cell leukemianatural killer cell leukemia (disease)NK cell leukaemiaNK cell leukemiaNK-cell large granular lymphocyte leukaemiaNK-cell large granular lymphocyte leukemia
Summary
aggressive NK-cell leukemia (MONDO:0019470) is a cancer and 9 clinical trials. Top therapeutic interventions include fludarabine phosphate, blinatumomab, and calaspargase pegol. A subtype of mature T-cell and NK-cell non-Hodgkin lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Prevalence: Unknown (Europe)
- Clinical trials: 9
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | aggressive NK-cell leukemia |
| Mondo ID | MONDO:0019470 |
| Orphanet | 86873 |
| DOID | DOID:1035 |
| ICD-11 | 153957345 |
| NCIT | C8647 |
| SNOMED CT | 721310007 |
| UMLS | C1292777 |
| MedGen | 266235 |
| GARD | 0010493 |
| MedDRA | 10028811 |
| Is cancer (heuristic) | yes |
Also known as: aggressive natural killer cell leukaemia · aggressive natural killer cell leukemia · aggressive NK cell leukaemia · aggressive NK cell leukemia · aggressive NK-cell leukaemia (morphologic abnormality) · aggressive NK-cell leukemia · aggressive NK-cell leukemia (morphologic abnormality) · aggressive NK-cell leukemia/lymphoma · aggressive NK-cell lymphoma · ANKCL · ANKL · leukaemia (disease) of natural killer cell · leukemia (disease) of natural killer cell · natural killer cell leukaemia (disease) · natural Killer cell leukemia · natural killer cell leukemia · natural killer cell leukemia (disease) · NK cell leukaemia · NK cell leukemia · NK-cell large granular lymphocyte leukaemia (+5 more)
Disease family
This is a subtype of mature T-cell and NK-cell non-Hodgkin lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › hematopoietic and lymphoid system neoplasm › hematopoietic and lymphoid cell neoplasm › lymphoid neoplasm › T-cell and NK-cell neoplasm › neoplasm of mature T-cells or NK-cells › mature T-cell and NK-cell non-Hodgkin lymphoma › aggressive NK-cell leukemia
Related subtypes (7): angioimmunoblastic T-cell lymphoma, systemic Epstein-Barr virus-positive T-cell lymphoproliferative disease of childhood, hydroa vacciniforme-like lymphoma, T-cell prolymphocytic leukemia, T-cell large granular lymphocyte leukemia, anaplastic large cell lymphoma, breast implant-associated anaplastic large cell lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 9.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| Not specified | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03849651 | PHASE2 | ACTIVE_NOT_RECRUITING | TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies |
| NCT05475925 | PHASE1/PHASE2 | RECRUITING | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas |
| NCT05863234 | PHASE1/PHASE2 | RECRUITING | Safety Evaluation Study for Patients With Aggressive NK-cell Leukemia |
| NCT05941156 | PHASE2 | RECRUITING | Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell Leukemia |
| NCT00890747 | PHASE1 | COMPLETED | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy |
| NCT01231919 | PHASE1 | COMPLETED | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia |
| NCT03719105 | EARLY_PHASE1 | RECRUITING | Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma |
| NCT05978141 | Not specified | RECRUITING | A Registry for People With T-cell Lymphoma |
| NCT00112593 | Not specified | COMPLETED | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| FLUDARABINE PHOSPHATE | 4 | 2 |
| BLINATUMOMAB | 4 | 1 |
| CALASPARGASE PEGOL | 4 | 1 |
| DIBOTATUG | 2 | 1 |